Lemaitre Vascular, Inc.
A maker of medical devices for vascular surgery, headquartered outside Boston. Its products — including the UniFit graft and Valvulotome — help surgeons treat conditions like peripheral artery disease and maintain dialysis access, used by doctors in hospitals around the world. The company takes its name from its founder, George LeMaitre, a surgeon who built the business around devices he designed for the operating room.
Granted 86.3K · Sold 252.4K
Granted 8.5K
Granted 5.5K
Granted 6.1K · Sold 11.8K
Granted 6.1K · Sold 5.0K
Granted 3.9K · Sold 3.9K
Granted 1.0K
Granted 7.2K · Sold 6.6K
Granted 1.0K
Granted 1.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| LeMaitre George WChairman and CEO, Director · 38 transactions | — | 2.93M | 86.3K | — | 252.4K |
| O'Connor John JamesDirector · 10 transactions | +9.6% | 62.8K | 8.5K | — | — |
| Pellegrino Joseph P JRDirector · 11 transactions | +53.8% | 15.0K | 5.5K | — | — |
| Roberts David BPresident and Director, Director · 25 transactions | -18.4% | 14.7K | 6.1K | — | 11.8K |
| Ross Bridget ADirector · 11 transactions | +208.2% | 9.0K | 6.1K | — | 5.0K |
| Jasinski Lawrence JDirector · 12 transactions | +63.3% | 7.8K | 3.9K | — | 3.9K |
| Roush John ADirector · 8 transactions | — | 4.3K | 1.0K | — | — |
| Kamke Trent GSenior V. P., Operations · 24 transactions | -0.1% | 3.7K | 7.2K | — | 6.6K |
| Shadan MarthaDirector · 8 transactions | +52.9% | 3.0K | 1.0K | — | — |
| LeBlanc Dorian PaulChief Financial Officer · 3 transactions | +88.5% | 2.3K | 1.2K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -279.8K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.